Abcellera Biologics/$ABCL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Abcellera Biologics
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
- Ticker
- $ABCL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 562
- Headquarters
- Vancouver, Canada
- Website
- www.abcellera.com
ABCL Metrics
BasicAdvanced
$4B
-
-$0.55
1.41
-
Price and volume
Market cap
$4B
Beta
1.41
52-week high
$15.02
52-week low
$2.75
Average daily volume
4.7M
Financial strength
Current ratio
12.77
Quick ratio
11.226
Long term debt to equity
0.145
Total debt to equity
0.145
Profitability
EBITDA (TTM)
-199.96
Gross margin (TTM)
-198.88%
Net profit margin (TTM)
-248.84%
Operating margin (TTM)
-340.27%
Effective tax rate (TTM)
16.32%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-10.39%
Return on equity (TTM)
-17.30%
Valuation
Price to revenue (TTM)
55.967
Price to book
4.2
Price to tangible book (TTM)
4.63
Price to free cash flow (TTM)
-30.946
Free cash flow yield (TTM)
-3.23%
Free cash flow per share (TTM)
-0.396
Growth
Revenue change (TTM)
101.27%
Earnings per share change (TTM)
-2.55%
3-year revenue growth (CAGR)
-23.04%
3-year earnings per share growth (CAGR)
27.97%
What the Analysts think about ABCL
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
Analyst projections of the future price of Abcellera Biologics stock.
Bulls say / Bears say
The Jazz and Vertex collaborations offer more than $100 million in upfront payments, with further milestone and royalty potential. Vertex will also fund research and development costs under its agreement, giving AbCellera a partner-backed route to advance its T-cell-engager platform. (AbCellera, AbCellera)
Beyond ABCL635, ABCL575 has completed Phase 1 dosing, with results expected in Q4, while ABCL386 and ABCL688 are in IND-enabling work. These programmes provide further pipeline opportunities and upcoming data catalysts. (AbCellera)
Q2 revenue fell to $4.1 million from $17.1 million a year earlier, while the net loss widened to $55.4 million from $34.7 million. The results show that revenue remains modest and losses are increasing as the company invests in research and development. (AbCellera)
AbCellera raised $200 million by selling 17.4 million shares and warrants for up to 3.1 million more. The capital supports development, but issuing these securities dilutes existing shareholders. (AbCellera)
The positive ABCL635 Phase 2 result came from 92 participants after a single dose, with the main efficacy comparison at four weeks. Longer-term benefit and safety, and success in later-stage testing, are not yet established. (AbCellera)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
ABCL Financial Performance
Revenues and expenses
ABCL Earnings Performance
Company profitability
Upcoming events
No upcoming events
ABCL News
AllArticlesVideos
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Business Wire3 weeks ago
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Business Wire2 months ago
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Business Wire2 months ago
Funds containing ABCL
Fund name | Fund size | $ABCL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.30% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.30% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.30% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.27% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.